DB17497InvestigationalVaccines
Autogene cevumeran is an mRNA-based cancer vaccine targeting an unspecified amount of tumour-associated antigens. It is being investigated for cancers.
- Code names
- RO-7198457
Resolves to
Compound
What you can answer from here — as of April 23, 2025
Which companies are running trials of Autogene cevumeran, in which indications and phases, and which of those programs are still active?
Create a free account or log in to explore the full data card.
Create Account